Fortress Biotech
Update in progressFBIO (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Fortress Biotech, Inc. is a biopharmaceutical company focused on developing and commercializing medicines across dermatology, oncology, infectious disease, and related areas. Its portfolio includes Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, Luxamend, Tramadol, CUTX-101, UNLOXCYT, Olafertinib, CAEL-101, Triplex, and early-stage programs such as Dotinurad, MB-101, MB-108, MB-109, MB-106, AJ201, BAER-101, plus preclinical gene therapies and other platforms. Formerly Coronado Biosciences; renamed in 2015. Based in Bay Harbor Islands, Florida, since 2006.
Company score
- Sentiment
- -0.12
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.03
- Governance
- -0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.06
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!